Ruth Lopert

Tabs

Bio

Dr. Lopert holds an adjunct appointment in the Department of Health Policy, where she was previously a Visiting Professor in 2011-2012. From 2008-11 Dr. Lopert was chief medical officer in the FDA’s Australian counterpart agency, the Therapeutic Goods Administration and in 2006-07 was a Commonwealth Fund Harkness Fellow in Health Policy. Previously, Dr. Lopert established and directed the Pharmaceutical Policy Taskforce in the Australian Department of Health and Ageing, responsible for developing policy options to support the long-term sustainability of the country’s pharmaceutical benefits program. She has also previously served as director of the AU$9 billion program and as a clinical and technical adviser to the program’s expert formulary committee.

Expertise

Education:

BSc (pure mathematics), Australian National University (ACT)

BMed (MD), University of Newcastle (NSW)

MMedSc (public health, pharmacoepidemiology), University of Newcastle (NSW)

Fellow of the Faculty of Public Health Medicine, Royal Australasian College of Physicians

Teaching:

PUBH 6374.10 - Pharmaceutical Policy (Spring 2012)

PUBH 6399:20 - Intro to Comparative Effectiveness Research / Health Technology Assessment: Methods and Policy (Summer 2012)

Research

Research:

Dr. Lopert’s research interests focus on therapeutics regulation; comparative effectiveness research and health technology assessment; pharmaceutical policy; intellectual property (IP); and issues at the intersections of trade, IP, and access to medicines.

Publications

Publications:

Assessing the impact of alternative patent systems on the cost of health care: the TPPA and HIV treatment in Vietnam. Moir H, Tenni B, Gleeson D, Lopert R. Assessing the impact of alternative patent systems on the cost of health care: the TPPA and HIV treatment in Vietnam. http://papers.ssrn.com/sol3 /papers.cfm?abstract_id= 2536254

Pharmacoeconomics as a Response to Market Failure: An International Perspective. Lopert R. Pharmacoeconomics as a Response to Market Failure: An International Perspective. Chapter in: Handbook of Pharmaceutical Public Policy, 2nd Ed. Edited by Fulda TR, Wertheimer AI. Haworth Press (forthcoming, 2015)

Transferability of results of cost utility analyses for biological in inflammatory conditions for Central and Eastern European countries. Gulácsi L, Rencz F, Péntek M, Brodszky V, Lopert R, Hevér N, Baji P. Transferability of results of cost utility analyses for biological in inflammatory conditions for Central and Eastern European countries. Eur J Health Econ 2014, DOI 10.1007/s10198-014-0591-7

Faecal microbiota transplantation: A sui generis biological drug, not a tissue. Megerlin F, Fouassier E, Lopert R, Bourlioux P. Faecal microbiota transplantation: A sui generis biological drug, not a tissue. Ann Pharm France 2014; 72(4):217–220

Revolution then evolution: The advance of health economic evaluation in Australia. Lopert R, Viney R. Revolution then evolution: The advance of health economic evaluation in Australia. Zeitschrift für Evidenz, Fortbildung und Qualität im Gesundheitswesen 2014, http://dx.doi.org/10.1016/j.zefq.2014.08.020

Substitution des biomédicaments: Prospective d’impact compétitif en droit comparé franco-américain. Megerlin F, Lopert R. Substitution des biomédicaments: Prospective d’impact compétitif en droit comparé franco-américain. Techniques Hospitalières 2014;748:37-43

The high price of “free” trade: US free trade agreements and access to medicines. Lopert R, Gleeson D. The high price of “free” trade: US free trade agreements and access to medicines. J Law Med Ethics 2013;41(1):199-223

Australia’s ‘Fourth Hurdle’ drug review comparing costs and benefits holds lessons for the United States. Lopert R, Elshaug AG. Australia’s ‘Fourth Hurdle’ drug review comparing costs and benefits holds lessons for the United States. Health Affairs 2013;32(4)778-78

Biosimilars and the European Experience: Implications for the United States. Megerlin F, Lopert R, Taymor K, Trouvin J-H. Biosimilars and the European Experience: Implications for the United States. Health Affairs 2013 32:1803-1810

Increased risk of intussusception associated with rotavirus vaccines in Australia’s national immunization program. Carlin J, Macartney K, Lee K, Quinn H, Buttery J, Lopert R, Bines J, McIntyre P. Increased risk of intussusception associated with rotavirus vaccines in Australia’s national immunization program. Clin Inf Dis 2013;57(10):1427-1434 Applying rapid ‘de facto’ HTA in resource-limited settings: Experience from Romania. Lopert R, Ruiz F, Chalkidou K.

Applying rapid ‘de facto’ HTA in resource-limited settings: Experience from Romania. Health Policy 2013; 112 (3):202-208 Likely impact of the Trans Pacific Partnership Agreement on access to affordable medicines and health equity in New Zealand. Gleeson D, Lopert R, Reid P.

Likely impact of the Trans Pacific Partnership Agreement on access to affordable medicines and health equity in New Zealand. Health Policy 2013;112(3):227-233

Impact of Medication Adherence on Medicare Expenditure among Beneficiaries with Heart Failure. Lopert R, Shoemaker JS, Stuart B, Davidoff A et al. Impact of Medication Adherence on Medicare Expenditure among Beneficiaries with Heart Failure. Am J Man Care 2012;18(9):556-63

Simulated Value-Based Insurance Design Applied to Statin Use by Medicare Beneficiaries with Diabetes. Davidoff A, Lopert R, Stuart B, Shaffer T et al. Simulated Value-Based Insurance Design Applied to Statin Use by Medicare Beneficiaries with Diabetes. Value in Health 2012;15(3):404-11

Does Medication Adherence Lower Medicare Spending among Medicare Beneficiaries with Diabetes? Stuart B, Davidoff A, Lopert R, Shaffer T, Shoemaker JS, Lloyd J. Does Medication Adherence Lower Medicare Spending among Medicare Beneficiaries with Diabetes? Health Services Research 2011;46(4):1180-89 (Winner of the 2011 John M. Eisenberg Article of the Year)

Web 2019 Update - CSS

Ruth

Lopert, BSc, BMed, MMedS, FAFPHM

Professorial Lecturer

Ruth Lopert

Tabs